Biopure Regains Nasdaq Listing Compliance CAMBRIDGE, Mass., June 15 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: BPURD; BPUR) announced today that it has received notification from The Nasdaq Stock Market that the company has regained compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq National Market, pursuant to Marketplace Rule 4450(a)(5). Biopure Corporation Biopure Corporation develops and manufactures intravenously administered pharmaceuticals, called oxygen therapeutics, that deliver oxygen to the body's tissues. The company is developing Hemopure(R) [hemoglobin glutamer - 250 (bovine)], or HBOC-201, for a potential indication in cardiovascular ischemia and, in collaboration with the U.S. Naval Medical Research Center, for an out- of-hospital trauma indication. The product is approved in South Africa for treating surgery patients who are acutely anemic and for eliminating, delaying or reducing allogeneic red blood cell transfusions in these patients. Hemopure has not been approved for sale in any other jurisdictions, including the United States or the European Union. Biopure's veterinary product Oxyglobin(R) [hemoglobin glutamer - 200 (bovine)], or HBOC-301, the only oxygen therapeutic approved by the U.S. Food and Drug Administration and the European Commission, is indicated for the treatment of anemia in dogs. Contact: Douglas Sayles Biopure Corporation (617) 234-6826 DATASOURCE: Biopure Corporation CONTACT: Douglas Sayles of Biopure Corporation, +1-617-234-6826, Web site: http://www.biopure.com/ Company News On-Call: http://www.prnewswire.com/comp/131224.html

Copyright